Dashboard
Manage Tickers

SWTXSpringWorks Therapeutics, Inc.

Nasdaq springworkstx.com


$ 39.21 $ 0.45 (1.16 %)    

Monday, 09-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 39.2
$ 38.52
$ 39.14 x 200
-- x --
$ 38.52 - $ 39.70
$ 18.00 - $ 53.92
579,029
na
2.91B
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-12-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-68
JP Morgan Maintains Overweight on SpringWo...
09/04/2024 22:02:40

JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...

hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-76-price-target
HC Wainwright & Co. Reiterates Buy on Spri...
08/28/2024 14:18:28

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $76 ...

springworks-says-european-medicines-agency-has-validated-marketing-authorization-application-for-mirdametinib-for-treatment-of-adult-and-pediatric-patients-with-nf1-pn
SpringWorks Says European Medicines Agency...
08/28/2024 10:35:36

Mirdametinib has the potential to be the first approved therapy for the treatment of adult patients and a best-in-class therapy...

springworks-therapeutics-says-fda-accepted-new-drug-application-and-granted--priority-review-for-mirdametinib-to-treat-neurofibromatosis-type-1-associated-plexiform-neurofibromas
SpringWorks Therapeutics Says FDA Accepted...
08/28/2024 10:33:39

The NDA was granted Priority Review and has been given a Prescription Drug User Fee Act (PDUFA) action date of February 28, 2025.

springworks-therapeutics-q2-2024-gaap-eps-054-beats-113-estimate-sales-59733m-beat-34343m-estimate
SpringWorks Therapeutics Q2 2024 GAAP EPS ...
08/07/2024 10:38:01

SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate...

springworks-therapeutics-has-completed-the-submission-of-a-new-drug-application-to-the-fda-for-mirdametinib-for-pediatric-and-adult-patients-with-neurofibromatosis-type-1--associated-plexiform-neurofibromas
SpringWorks Therapeutics Has Completed The...
07/01/2024 10:32:15

In the second half of 2024, SpringWorks also plans to file a Marketing Authorization Application (MAA) with the European Medici...

Core News & Articles
SpringWorks Therapeutics Inc Says Terminat...
06/07/2024 20:27:06

- SEC Filing

Core News & Articles
SpringWorks Therapeutics Says Termination ...
06/07/2024 20:26:22

- SEC Filing

Core News & Articles
SpringWorks Therapeutics Says Deal Termina...
06/07/2024 20:25:37

- SEC Filing

Core News & Articles
SpringWorks Therapeutics Got Notice Of Ter...
06/07/2024 20:24:07

- SEC Filing

hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target
HC Wainwright & Co. Reiterates Buy on Spri...
06/04/2024 10:48:49

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target
HC Wainwright & Co. Reiterates Buy on Spri...
05/31/2024 10:16:18

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target
HC Wainwright & Co. Reiterates Buy on Spri...
05/06/2024 10:35:24

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

springworks-cash-cash-equivalents-and-marketable-securities-were-573m-as-of-march-31-2024
Springworks' Cash, Cash Equivalents And Ma...
05/02/2024 10:35:37

springworks-therapeutics-q1-2024-gaap-eps-118-misses-116-estimate-sales-21006m-beat-12206m-estimate
SpringWorks Therapeutics Q1 2024 GAAP EPS ...
05/02/2024 10:32:52

SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.18) per share which missed the analyst consensus estima...

hc-wainwright--co-maintains-buy-on-springworks-therapeutics-raises-price-target-to-74
HC Wainwright & Co. Maintains Buy on Sprin...
03/06/2024 13:30:20

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the pric...

jp-morgan-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-74
JP Morgan Maintains Overweight on SpringWo...
03/06/2024 11:38:41

JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...

springworks-therapeutics-has-initiated-a-rolling-submission-of-a-new-drug-application-to-fda-for-mirdametinib-in-pediatric-and-adult-patients-with-neurofibromatosis-type-1-associated-plexiform-neurofibromas-expected-to-complete-by-q2-of-2024
SpringWorks Therapeutics Has Initiated A R...
03/04/2024 11:37:23

springworks-therapeutics-announces-european-medicines-agency-validation-for-marketing-authorization-application-of-nirogacestat-for-treatment-of-adults-with-desmoid-tumors
SpringWorks Therapeutics Announces Europea...
02/29/2024 14:02:12

barclays-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-63
Barclays Maintains Overweight on SpringWor...
02/29/2024 13:26:58

Barclays analyst Peter Lawson maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION